BIGBEAR Pharmaceutical announces the approval of Larotrectinib in Laos

Vientiane, Laos - May 30, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that Larotrectinib have been approved by the Ministry of Health of Laos.


Approved drugs are:

Larotrectinib: sold under the brand name LARODX. Larotrectinib is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. Larotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion.Some clinical trial results were announced in 2017. On 26 November 2018, Larotrectinib was approved by the FDA.

  • Lao registered trade name: Lao Reg No.: 04L1086/24 100mg

  • Lao registered trade name: Lao Reg No.: 04L1087/24 25mg


About BigBear Pharmaceuticals:

BigBear Pharmaceuticals is headquartered in Vientiane, the capital of Laos. The company is committed to drug research and development, production and sales, providing high-quality, safe and effective pharmaceutical products. BigBear Pharmaceuticals has established a good reputation in the Lao drug market with its excellent professional knowledge and innovation capabilities, and actively participates in international pharmaceutical cooperation and exchanges.


Forward-Looking Statements:

Within the scope of applicable laws and regulations, "plans," "goals," "expectations," "forecasts" and other similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that could differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulatory and/or economic conditions, uncertainties in clinical study results, exposure to various market risks and other factors beyond the Company's control.